Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2021 02:00 ET | Source: Novartis Pharma AG

Novartis to sell its Roche stake in a bilateral transaction to Roche

Ad hoc announcement pursuant to Art. 53 LR Novartis and Roche agree a bilateral transaction for the sale of Roche bearer shares held by Novartis for a total consideration of USD 20.7 billion ...
October 29, 2021 15:46 ET | Source: Novartis Pharma AG

FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine...
October 26, 2021 01:00 ET | Source: Novartis Pharma AG

Novartis réalise de solides résultats au 3e trimestre, avec une forte croissance d’Innovative Medicines, et annonce un examen stratégique de Sandoz

Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T3 en progression de +5% (tcc¹, +6% USD)Innovative Medicines: hausse de +7% (tcc, +8% USD)Forte performance des moteurs de...
October 26, 2021 01:00 ET | Source: Novartis Pharma AG

Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz

Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +5% (cc¹, +6% USD) Innovative Medicines grew +7% (cc, +8% USD)Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx...
October 26, 2021 01:00 ET | Source: Novartis Pharma AG

Novartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz an

Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz stieg im dritten Quartal um +5% (kWk¹, +6% USD) Die Division Innovative Medicines wuchs um +7% (kWk, +8% USD)Starke Performance der wichtigsten...
October 25, 2021 01:15 ET | Source: Novartis Pharma AG

Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer

Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS) in...
October 19, 2021 01:15 ET | Source: Novartis Pharma AG

Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer

Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease...
October 11, 2021 03:15 ET | Source: Novartis Pharma AG

Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics

Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading...
October 01, 2021 11:52 ET | Source: Novartis Pharma AG

Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs

Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has...
September 30, 2021 01:15 ET | Source: Novartis Pharma AG

Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions

Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and universities...